Drug Trial Radar · NCT04625270
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Last checked: Nov 19, 2026Latest source record: Jan 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Dec 21, 2020
Primary completion
Nov 15, 2024
Study completion Dec 2026
Sponsor
- Lead sponsor
- Verastem, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
- First posted
- Nov 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Conditions
- Low Grade Ovarian Serous Adenocarcinoma
- Ovarian Cancer
Interventions
avutometinib (VS-6766)Drug
avutometinib (VS-6766) monotherapy
avutometinib (VS-6766) and defactinibDrug
avutometinib (VS-6766) and defactinib combination
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Determine optimal regimen of avutometinib (VS-6766) monotherapy or in combination with defactinibTime frame: From start of treatment to confirmation of response; 24 weeks
- Part B: To determine the efficacy of the optimal regimen identified from Part ATime frame: From start of treatment to confirmation of response; 24 weeks
- Part C: To evaluate additional efficacy parameters for the optimal regimen identified in Part ATime frame: From start of treatment to confirmation of response; 24 weeks
- Part D:To evaluate additional efficacy parameters for a lower dose of avutometinib in combination with defactinibTime frame: From start of treatment to confirmation of response; 24 weeks
Locations
47 sites in 7 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates PC HAL
Scottsdale, Arizona
Sansum Clinic
Santa Barbara, California
Yale School of Medicine
New Haven, Connecticut
Advent Health
Orlando, Florida
H. Lee Moffitt Cancer Center and Research Institute - Center for Women's Oncology
Tampa, Florida
University of Chicago
Chicago, Illinois
Maryland Oncology and Hematology, P.A.
Glenn Dale, Maryland
Minnesota Oncology Hematology PA
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico
Memorial Sloan Kettering Cancer Center
New York, New York
Cleveland Clinic Women's Health Institute
Cleveland, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
University of Oklahoma Medical Center
Oklahoma City, Oklahoma
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon
Northwest Cancer Specialists
Portland, Oregon
Sarah Cannon Research Institute
Nashville, Tennessee
Texas Oncology Austin Central
Austin, Texas
Texas Oncology- Dallas Presbyterian Hospital
Dallas, Texas
UT Southwestern Medical Center
Dallas, Texas
Texas Oncology
Longview, Texas
Texas Oncology
McAllen, Texas
Texas Oncology
San Antonio, Texas
Texas Oncology
The Woodlands, Texas
University of Virginia Health System
Charlottesville, Virginia
Virginia Cancer Specialists, PC
Gainesville, Virginia
UZ Gent Medische Oncologie
Ghent, Belgium
UZ Leuven
Leuven, Belgium
CHU de Liege
Liège, Belgium
Centre de recherche di Centre Hospitalier de i'Universite de Montreal
Montreal, Canada
Princess Margaret Cancer Centre
Toronto, Canada
Hopital Jean Minjoz
Besançon, France
Centre Leon Berard
Lyon, France
ICM - Val d'Aurelle
Montpellier, France
Institut Curie
Paris, France
Insituto Europeo di Oncologia I.R.C.C.S
Milan, Italy
U.O.C. Oncologia 2, Istituto Oncologico Veneto I.R.C.C.S.
Padova, Italy
Hospital Universitario Vall D'Hebron
Barcelona, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.